Boardroom Alpha
Boardroom Alpha
MLSS · Current Report (Form 8-K) · Filed December 23, 2025

Milestone Scientific Inc — Current Report (Form 8-K)

Form
8-K
Filed
December 23, 2025
Period
Dec 18, 2025
Ticker
MLSS
Accession
0001493152-25-029067
Boardroom Alpha · Filing insights

Stockholders re-elected six incumbent directors, approved increasing authorized common shares to 125,000,000, and ratified CBIZCPA P.C. as auditors.

About Milestone Scientific Inc
Market cap
$34M
1Y TSR
−56.0%
3Y TSR
−28.0%
Board grade
C-
Sector
Healthcare
CEO
Eric Hines
Last annual meeting: Dec 18, 2025 · View full Milestone Scientific Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 18, 2025

 

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-14053   13-3545623

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

425 Eagle Rock Avenue, Suite 403

Roseland, NJ

  07068

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (973) 535-2717

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name on exchange on which registered
Common Stock   MLSS   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

The 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Milestone Scientific Inc. (the “Company”) was held on December 18, 2025. At the Annual Meeting, the Company’s stockholders:

 

Elected six incumbent directors to serve until the next annual meeting of the Company’s stockholders or until their respective successors have been duly elected and qualified;
  
Approved an amendment to the Company’s Restated Certificate of Incorporation increasing the number of authorized shares of Common Stock from 100,000,000 to 125,000,000; and
  
Ratified the appointment of CBIZCPA P.C. as the Company’s independent auditors for the fiscal year ending December 31, 2025.

 

The total number of shares outstanding at the record date for the Annual Meeting was 78,628,913 shares of common stock. The total number of shares voted at the Annual Meeting was 48,381,413 shares of common stock, representing 61.53% of the issued and outstanding shares of common stock.

 

The number of votes cast for, against or withheld and the number of abstentions and broker non-votes with respect to each Proposal is set forth below.

 

PROPOSAL #001 ELECTION OF DIRECTORS INCLUDING DIRECTOR EXCEPTIONS

 

***   FOR   % VOTED FOR   WITHHELD   % VOTED WITHHELD
BENEDETTA I. CASAMENTO   25,471,050   85.92%   4,173,862   14.08%
NEAL GOLDMAN   26,283,035   88.66%   3,361,877   11.34%
ERIC HINES   29,184,965   98.45%   459,947   1.55%
DR. DIDIER DEMESMIN   25,788,621   86.99%   3,856,291   13.01%
SHANTH THIYAGALINGAM   29,147,090   98.32%   497,822   1.68%
DR. DAWOOD SAYED   29,264,979   98.72%   379,933   1.28%
TOTAL ALL DIRECTORS   165,139,740       12,729,732    
DIRECTOR AVERAGE   27,523,290       2,121,622    
% VOTED OF AVERAGE   92.84%       7.16%    

 

PROPOSAL #002 APPROVAL TO AMEND THE RESTATED CERTIFICATE OF INCORPORATION

 

***   FOR   AGAINST   ABS/WHD   BROKER NON-VOTES
BENEFICIAL   42,491,824   1,845,895   26,055    
REGISTERED   4,017,639   0   0    
TOTAL SHARES VOTED   46,509,463   1,845,895   26,055    
% OF VOTED   96.18%   3.81%        
% OF OUTSTANDING   59.15%   2.34%        
% OF VOTED W/ABS/WHD   96.13%   3.81%   0.05%    
% OF OUTSTNDG W/ABS/WHD   59.15%   2.34%   0.03%    

 

PROPOSAL #003 RATIFY CBIZ CPAS P.C. AS INDEPENDENT AUDITORS

 

***   FOR   AGAINST   ABS/WHD   BROKER NON-VOTES
BENEFICIAL   43,580,300   542,809   240,665    
REGISTERED   4,017,639   0   0    
TOTAL SHARES VOTED   47,597,939   542,809   240,665    
% OF VOTED   98.87%   1.12%        
% OF OUTSTANDING   60.53%   0.69%        
% OF VOTED W/ABS/WHD   98.38%   1.12%   0.49%    
% OF OUTSTNDG W/ABS/WHD   60.53%   0.69%   0.30%    

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Milestone Scientific Inc. 
     
Dated: December 23, 2025 By: /s/ Eric Hines
    Eric Hines
    Chief Executive Officer

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Milestone Scientific Inc (MLSS)

Reference

Frequently asked questions

When did Milestone Scientific Inc file this 8-K?
Milestone Scientific Inc (MLSS) filed this Current Report (Form 8-K) with the SEC on December 23, 2025. The accession number assigned by EDGAR is 0001493152-25-029067.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders re-elected six incumbent directors, approved increasing authorized common shares to 125,000,000, and ratified CBIZCPA P.C. as auditors. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Milestone Scientific Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Milestone Scientific Inc has filed under CIK 855683, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer